Pakistan's fashion designers reinvigorate industry after difficult year
After a year on pause, Pakistan’s fashion industry is coming back to life
The two-day Fashion Pakistan Week took place in Karachi
Pakistan's fashion designers reinvigorate industry after difficult year
After a year on pause, Pakistan’s fashion industry is coming back to life
The two-day Fashion Pakistan Week took place in Karachi
The Charlotte Hornets’ renewed attention to detail in drafting and development has seen players like McDaniels grww from a late draft picks to impactful fill-in starters.
French container shipping group CMA CGM is pursuing a plan to rebuild Beirut's port within three years, despite political deadlock in Lebanon that has prevented decisions on the port since a blast last August, a company executive said. A chemical explosion at the port killed 200 people and destroyed entire neighbourhoods, deepening Lebanon's worst political and economic crisis since the 1975-1990 civil war. CMA CGM's plan, first outlined to Lebanese authorities in September, envisages the reconstruction of damaged docks and warehouses, along with port expansion and digitalisation, at a total cost estimated at $400 million to $600 million, Joe Dakkak, general manager CMA CGM Lebanon, said on Saturday.
Gun salutes across the U.K., in Commonwealth countries and at sea marked the death of Britain's Prince Philip on Saturday as military leaders honored the former naval officer and husband of Queen Elizabeth II.
An Italian prosecutor on Saturday told a court in Sicily that there's no reason to order right-wing leader Matteo Salvini to stand trial for alleged kidnapping for his role in keeping rescued migrants aboard a coast guard ship for days in the summer of 2019. Prosecutor Andrea Bonomo recommended at a preliminary hearing in Catania that Salvini was carrying out government policy when he kept 116 migrants aboard the Italian coast guard vessel Gregoretti off the coast of Sicily for five days. At the time, Salvini was Italy's interior minister in a government headed by Premier Giuseppe Conte.
NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of SOS Limited (“SOS” or the “Company”) (NYSE: SOS) from July 22, 2020, through February 25, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934. If you purchased SOS securities, and/or would like to discuss your legal rights and options please visit SOS Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. On February 26, 2021 Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) released commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used fake addresses and doctored photos of crypto rigs to create an illusion of success. On this news, SOS’s American depositary share (“ADS”) price fell $1.27 per share, or 21.03%, to close at $4.77 per ADS on February 26, 2021. If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased SOS securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/soslimited-sos-shareholder-class-action-lawsuit-stock-fraud-384/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information Matthew E. GuarneroBernstein Liebhard LLPhttps://www.bernlieb.com(877) 779-1414MGuarnero@bernlieb.com
Egypt’s best-known archaeologist on Saturday revealed further details on a Pharaonic city recently found in the southern province of Luxor. Zahi Hawass said that archaeologists found brick houses, artifacts, and tools from pharaonic times at the site of the 3,000-year-old lost city. It dates back to Amenhotep III of the 18th dynasty, whose reign is considered a golden era for ancient Egypt.
Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and ActivationCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that preclinical data from FS222, a potentially best-in-class tetravalent bispecific antibody targeting both CD137 and PD-L1 will be presented in a poster at the 2021 American Academy of Cancer Research (AACR) Annual Meeting, taking place virtually from April 10-15 and May 17-21. Poster #1864, entitled ‘FS222, a Tetravalent Bispecific Antibody Targeting CD137 and PD-L1, is Designed for Optimal CD137 Interactions Resulting in Potent T cell Activation Without Toxicity’ will be available via on-demand viewing starting today, April 10, at 8:30 a.m. ET. FS222 targets PD-L1, the immune checkpoint protein that regulates the balance of activated T cells in the immune system and is overexpressed on many solid tumors and CD137, a co-stimulatory molecule from the tumor necrosis factor receptor superfamily (TNFRSF), which is widely known to be upregulated on tumor-reactive CD8+ T cells or “killer T cells”. Currently, only a minority of patients have a long-lasting response to monotherapies that block the PD-(L)1 pathway. Neil Brewis, Chief Scientific Officer at F-star Therapeutics, said: “We are encouraged by the results of these latest preclinical studies of FS222, our tetravalent bispecific antibody targeting PD-L1 and CD137. This work further demonstrates that FS222’s tetravalent binding mechanism is the most efficient and effective format for bispecific antibodies. The early onset of activity and T cell proliferation gives us confidence that FS222 will allow for a wide range of treatment options.” FS222 was designed to be a potent human CD137/PD-L1 tetravalent conditional agonist with a unique combination of high affinity PD-L1 binding, and moderate affinity, but with high avidity, binding to CD137 on activated T cells to result in optimal receptor clustering. Previously, FS222 has been shown to exhibit a favorable safety profile in preclinical safety studies. Tetravalent binding by FS222 demonstrated optimal activity in multiple preclinical pharmacology studies, outperforming classic heterodimeric bispecific antibodies. These data showed that there was no evidence of a hook effect, or bell-shaped dose response curve, in vitro, and coupled with FS222’s favorable safety profile, presents a potentially broad and differentiated therapeutic window. A murine surrogate mAb2 for FS222 had peripheral immunopharmacology, as shown by CD8+ T cell proliferation, at high dose levels, mirroring the in vitro data, whereby the tetravalent FS222 surrogate mAb2 outperforms other lower valency formats. In January 2021, F-star announced that the first patient had been dosed in a Phase 1 clinical trial of FS222, a multicenter, open-label, first-in-human trial to evaluate the safety, tolerability, and early signs of efficacy of FS222 in adult patients diagnosed with advanced malignancies. The adaptive study design will allow for the early exploration of clinical activity of FS222 in a range of selected solid tumors that will guide future targeted clinical development. About F-star Therapeutics, Inc. F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability. For more information visit www.f-star.com and follow us on LinkedIn and Twitter. Forward Looking Statements Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. F-star undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including those discussed in F-star’s Annual Report on Form 10-K, as well as subsequent Quarterly Reports on Form 10-Q and other documents to be filed from time to time with the SEC. New factors emerge from time to time and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this communication are based on information available to F-star as of the date of this communication. F-star does not assume any obligation to update such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For further information, please contact: For investor inquiriesLindsey TrickettVP Investor Relations & Communications+1 firstname.lastname@example.org For media inquiriesHelen ShikShik Communications LLC+1 617-510-4373Shik.Helen10@gmail.com
"Brandon Bernard was a different person from the teenager arrested over 20 years earlier. Up until the end, he did not think he would be executed because he knew he had reformed."
Prince William has dropped out of this weekend’s BAFTA Awards, following the death of his grandfather, Prince Philip. BAFTA said in a statement: “In light of The Duke of Edinburgh’s passing, The Duke of Cambridge will no longer be part of BAFTA programming this weekend. Our thoughts are with the Royal Family, to whom we […]
Campbell talked about his staff on the first episode of Inside the Den
After co-piloting President Obama's efforts to fight climate change as vice president, Joe Biden is having his second go, releasing a broad infrastructure proposal his administration hopes will lead to meaningful legislation and investment into stemming U.S. greenhouse emissions. The big picture: Though there are no concrete programs yet — Congress will have to formulate those — many in venture capital are hopeful such programs will provide new opportunities for startups tackling climate change. Stay on top of the latest market trends and economic insights with Axios Markets. Subscribe for freeWhat they're saying: If these programs are done right, we could see a wave of new companies emerging from labs across a range of critical technology areas, a more diverse set of entrepreneurs spread across more regions of the country, better coordination between government and private sector on shared priorities, and more domestic manufacturing. ... Details in these programs matter a great deal for startups, as we all so painfully remember from the PPP debates last year. So we are going to be active and engaged on how the plan impacts the startup community, whether it's fighting to make startups eligible for energy tax credits, that new company formation is a priority in research and technology commercialization programs, that any U.S. manufacturing policy include support for the production scale-up of growth companies, and any other issues that may unintentionally make startups and growth companies ineligible for the programs created by the American Jobs Plan.Justin Field, National Venture Capital AssociationThe other side: While the administration's commitment to taking on this issue is widely praised by the industry, some don't think the sector will need the government. [W]e aren't counting on the government's direct help in our investment thesis. Why? Today, with shared lab space, massive computing clusters available for rent, proliferation of machine learning, cheap renewable electricity, the discovery of CRISPR/Cas9, breakthroughs in electrochemistry, and more streamlined tech transfer from universities, true seed-stage climate tech startups are possible at scale. Some benefit from grants and government investment, and no doubt healthy public investment in research and science lifts all boats, but barely any of these climate tech companies count on governments for handouts because they increasingly can rely upon free markets to reward them with customers. Lowercarbon CapitalGo deeper: The top climate takeaways from Biden's sweeping infrastructure plan More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free
Apr. 10—CUMBERLAND — Representatives of the Allegany County NAACP branch asked county officials Thursday for transparency following an altercation between sheriff's office deputies and citizens during a recent eviction. A video posted to social media showed the chaotic incident, reportedly at a Hickory Avenue property in Bowling Green on April 5. Evictions routinely include the presence of ...
Apr. 10—River Valley High football closed out its condensed home schedule on Friday when Bella Vista came to town looking to finally put an end to that program-long 44-game losing streak. RV showed early on that it wasn't having any of Bella Vista's wishes, scoring four plays into its initial drive with the first of three touchdown runs from George Baker, setting the tone for a long night for ...
Apr. 10—JEFFERSONVILLE — A popular Indiana brewery has opened the doors of its riverfront location in Jeffersonville. The Bloomington-based Upland Brewing Co. officially opened its sixth location Friday at 707 W. Riverside Drive, formerly home to Buckhead Mountain Grill. David Bower, president of Upland Brewing Company, said he is amazed with the transformation of the 13,000-square-foot space ...
So many people have diabetes—about 1.5 million are diagnosed in the United States each year, and nearly 1 in 10 Americans have it—you'd think it'd be easy to spot. But although the condition is relatively common, many people go undiagnosed because the early symptoms can be vague, easily overlooked at first, or confused with other conditions. Here from Eat This, Not That! Health are the first signals your body might send when you develop diabetes. Read on to learn about the new study—and to ensure your health and the health of others, don't miss these Signs Your Illness is Actually Coronavirus in Disguise. 1 Increased Thirst A very common early sign of diabetes, increased thirst happens because diabetes causes sugar (glucose) to build up in the bloodstream. Normally, the kidneys process glucose, but when they become overwhelmed, the excess glucose is flushed out with your urine. Water from other body tissues is pulled along with it, leaving you dehydrated and craving fluids to replace what you've lost.The Rx: Experts such as Harvard Medical School advise drinking four to six cups of water per day. If you're hydrating adequately but you've noticed an uptick in thirst, talk with your doctor. 2 Frequent Urination In early diabetes, the body will increase urine production, attempting to flush out that excess blood sugar, and you might find yourself having to go more often. "It's important to know what is normal for your body," says Leigh Tracy, RD, LDN, CDE, a registered dietitian and diabetes program coordinator at Mercy Medical Center in Baltimore. "The average individual urinates between seven and eight times per day, but for some, up to 10 times per day is normal."The Rx: "If you are urinating more than your norm, and especially if you are waking up multiple times in the middle of the night to urinate, speak with your primary care physician right away," says Tracy. 3 Excessive Hunger Diabetes causes blood glucose to rise uncontrollably. At the same time, it prevents cells from using glucose for energy. That lack of energy can make you hungry.The Rx: "If you notice you're constantly hungry even though you have just eaten regular meals and snacks during the day, you should speak with your doctor," says Tracy. 4 Fatigue Because diabetes elevates blood sugar at the same time it prevents the body from using it for energy, that can make you fatigued. Frequent urination can also disrupt your sleep.The Rx: There's a difference between tiredness and fatigue. Normal tiredness gets better after rest. But if you still feel worn out despite getting an adequate amount of sleep, it's worth discussing with your doctor. 5 Blurred Vision According to the Mayo Clinic, high levels of blood glucose pull fluid from your tissues, including the lenses of your eyes. This can affect your ability to focus and cause blurry vision. Diabetes can also cause new blood vessels to form in the retinas, damaging established vessels. If those changes progress untreated, they can lead to vision loss.The Rx: If you're experiencing any signs of diabetes such as blurred vision, it's important to see your doctor ASAP, and regularly if you're diagnosed. "Diabetes is a progressive disease, even in patients with excellent lifestyles," says Sarah Rettinger, MD, an endocrinologist at Providence Saint John's Health Center in Santa Monica, California. 6 Cuts or Bruises That Won't Heal Diabetes can make skin injuries, such as cuts and bruises, slower to heal. High blood sugar can stiffen blood vessels, slowing blood flow and preventing oxygen and nutrients from getting to cuts and bruises to heal them. Diabetes can also impair the immune system, slowing the body's natural repair processes.The Rx: If you notice that cuts or bruises aren't healing as quickly as they have in the past, see your healthcare provider. 7 Unintentional Weight Loss Losing weight without any changes in diet or exercise may sound great, but it's the definition of too good to be true: It can signify a serious health condition such as hyperthyroidism, cancer or diabetes. When diabetics lose glucose through frequent urination, they also lose calories. Diabetes may also keep cells from absorbing glucose from food for energy, and the body may begin to burn its fat stores as fuel instead. Both can result in weight loss.The Rx: If you're shedding pounds without trying, see your doctor and ask if you should be tested for diabetes. 8 Tingling, Pain or Numbness In Hands or Feet Diabetes can lead to a kind of nerve damage called neuropathy, which can cause tingling or numbness in your extremities like hands or feet. This is dangerous because numbness can make cuts or injuries easier to overlook, and because diabetes can cause wounds to heal more slowly, complications can result.The Rx: Be aware of what's going on with your body, and if you're experiencing any unusual pain, numbness or tingling in your hands or feet, see a healthcare provider without delay. 9 No Symptoms "People often have no symptoms of diabetes," says Kristine Arthur, MD, an internist at MemorialCare Medical Group in Irvine, California. "Sometimes they may notice weight gain, persistent hunger and increased fatigue associated with high insulin levels, but these symptoms can be present in other conditions, so it is important to have blood tests done to find out what is the cause."The Rx: Have your HgbA1c (sometimes called "A1c") levels checked with a blood test every year during your routine checkup. And to get through this pandemic at your healthiest, don't miss these Sure Signs You've Already Had Coronavirus.
Apr. 10—CONNEAUT — Tellus Andrews went out for track as a freshman to improve as a football player, but instead of working on his quickness in sprinting events, he competed in distance events and the high jump because of Conneaut's depth in sprinting events. The Spartans featured a variety of impressive sprinters at the time, including Matt McBride and Josh Leggett. Andrews wanted to letter ...
The victim died at the scene after suffering serious head injuries.
The Titans landed right in the middle of the pack.
All private coronavirus tests will be subject to UK quality assurance checks, it has emerged as the Government admits too many are hitting the market that do not work properly. Ministers have set out plans to ensure that all new tests meet “minimum performance standards” because as few as 25 per cent of privately-made lateral flow devices are "of sufficient quality for procurement". The news comes after Number 10 announced that everyone in England will be offered twice-weekly Covid-19 tests as part of the push to “reclaim a more normal way of life”. Lateral flow test kits, which can provide results in just three minutes, are available for free through workplaces, at testing sites and via the post from last Friday. Under the plans, the Government will establish “a requirement that all Covid-19 tests placed on the UK market undergo a mandatory validation process”.